Sen. Tommy Tuberville Sells Amgen Inc. (NASDAQ:AMGN) Stock

Senator Tommy Tuberville (R-Alabama) recently sold shares of Amgen Inc. NASDAQ: AMGN. In a filing disclosed on May 15th, the Senator disclosed that they had sold between $15,001 and $50,000 in Amgen stock on April 15th.

Senator Tommy Tuberville also recently made the following trade(s):

• Sold $15,001 - $50,000 in shares of Duke Energy NYSE: DUK on 4/15/2025.
• Sold $15,001 - $50,000 in shares of CSX NASDAQ: CSX on 4/15/2025.
• Sold $1,001 - $15,000 in shares of Bristol-Myers Squibb NYSE: BMY on 4/15/2025.
• Sold $15,001 - $50,000 in shares of PayPal NASDAQ: PYPL on 4/15/2025.
• Sold $15,001 - $50,000 in shares of Constellation Brands NYSE: STZ on 4/15/2025.
• Sold $15,001 - $50,000 in shares of Alphabet NASDAQ: GOOGL on 4/15/2025.
• Sold $15,001 - $50,000 in shares of The Goldman Sachs Group NYSE: GS on 4/15/2025.
• Purchased $50,001 - $100,000 in shares of iShares Broad USD Investment Grade Corporate Bond ETF NASDAQ: USIG on 4/15/2025.
• Sold $15,001 - $50,000 in shares of Microsoft NASDAQ: MSFT on 4/15/2025.
• Sold $15,001 - $50,000 in shares of Mastercard NYSE: MA on 4/15/2025.

Amgen Price Performance

Amgen stock opened at $271.69 on Friday. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. The company has a market capitalization of $146.09 billion, a PE ratio of 35.99, a P/E/G ratio of 2.63 and a beta of 0.51. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85. The stock has a 50-day moving average price of $291.93 and a two-hundred day moving average price of $288.58.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.18 by $0.72. Amgen had a return on equity of 176.32% and a net margin of 12.24%. The company had revenue of $8.15 billion during the quarter, compared to the consensus estimate of $8.05 billion. During the same period last year, the company earned $3.96 earnings per share. The firm's revenue was up 9.4% compared to the same quarter last year. Analysts expect that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be given a $2.38 dividend. The ex-dividend date is Friday, May 16th. This represents a $9.52 annualized dividend and a yield of 3.50%. Amgen's dividend payout ratio is presently 86.86%.

Hedge Funds Weigh In On Amgen

Several institutional investors have recently bought and sold shares of AMGN. Brookstone Capital Management raised its holdings in Amgen by 8.2% in the 4th quarter. Brookstone Capital Management now owns 19,252 shares of the medical research company's stock worth $5,018,000 after purchasing an additional 1,462 shares during the period. Moody National Bank Trust Division raised its holdings in Amgen by 18.7% in the 4th quarter. Moody National Bank Trust Division now owns 925 shares of the medical research company's stock worth $241,000 after purchasing an additional 146 shares during the period. Grassi Investment Management raised its holdings in Amgen by 4.5% in the 4th quarter. Grassi Investment Management now owns 4,600 shares of the medical research company's stock worth $1,199,000 after purchasing an additional 200 shares during the period. Miracle Mile Advisors LLC raised its holdings in Amgen by 3.0% in the 4th quarter. Miracle Mile Advisors LLC now owns 6,016 shares of the medical research company's stock worth $1,568,000 after purchasing an additional 176 shares during the period. Finally, Signal Advisors Wealth LLC raised its holdings in Amgen by 11.2% in the 4th quarter. Signal Advisors Wealth LLC now owns 1,881 shares of the medical research company's stock worth $490,000 after purchasing an additional 190 shares during the period. 76.50% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Amgen news, EVP David M. Reese sold 25,225 shares of the stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the completion of the transaction, the executive vice president now owns 36,922 shares of the company's stock, valued at $11,240,533.68. This represents a 40.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.76% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. StockNews.com cut Amgen from a "strong-buy" rating to a "buy" rating in a report on Saturday, May 10th. Johnson Rice set a $294.00 price target on shares of Amgen in a research note on Wednesday, March 5th. Morgan Stanley restated an "equal weight" rating on shares of Amgen in a research note on Friday, May 2nd. Erste Group Bank lowered shares of Amgen from a "strong-buy" rating to a "hold" rating in a research note on Thursday, May 8th. Finally, UBS Group restated a "neutral" rating and set a $315.00 price target (down previously from $319.00) on shares of Amgen in a research note on Friday, May 2nd. Two analysts have rated the stock with a sell rating, eleven have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $310.23.

About Senator Tuberville

Tommy Tuberville (Republican Party) (also known as Coach) is a member of the U.S. Senate from Alabama. He assumed office on January 3, 2021. His current term ends on January 3, 2027. Tuberville (Republican Party) ran for election to the U.S. Senate to represent Alabama. He won in the general election on November 3, 2020. Tuberville was head coach for several college football teams between 1995 and 2016, including at Auburn University and the University of Cincinnati. Tommy Tuberville was born in Camden, Arkansas, and lives in Auburn, Alabama. Tuberville's career experience includes working as a studio analyst with ESPN and as the head football coach of the University of Mississippi, the University of Auburn, Texas Tech University, and the University of Cincinnati.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.